# David Berry, MD PhD

> David co-founded Averin with Eric with the goal of investing in GDP-defining opportunities with a focus on driving return for investors while bringing forth impactful innovations to society. He brings nearly two decades of investing, entrepreneurship, and company building experience to Averin.

## About

- [Home page](https://davidaberry.com/): Managing Partner & Co-Founder, Averin Capital
- [Full profile (llms-full.txt)](https://davidaberry.com/llms-full.txt): Complete bio, experience, education, board roles, and writing
- [Averin Capital](https://averincapital.com): Venture capital firm co-founded by David Berry

## Writing

- [The Surgeon Is Still the System](https://www.averincapital.com/insights/the-surgeon-is-still-the-system): The next era of surgery will not be defined by robots alone, but by integrated systems of AI, visualization, and precision tools that expand what surgeons…
- [Diagnostics Isn’t Broken. Our Model for Evaluating It Is](https://www.averincapital.com/insights/diagnostics-isnt-broken-our-model-for-evaluating-it-is): Investor sentiment has turned against diagnostics, but for the wrong reasons. Recent failures have hardened a lazy narrative that the category is…
- [Regulation, AI, and Geopolitics: Insights from Our Latest Fireside Chat](https://www.averincapital.com/insights/regulation-ai-and-geopolitics-insights-from-our-latest-fireside-chat): In a candid conversation with Peter Hutt, David Shulkin, and Daniel Troy, we cut through headline noise to find a clear pattern - despite few formal…
- [The FDA’s Shifting Regulatory Landscape](https://www.averincapital.com/insights/the-fdas-shifting-regulatory-landscape): The FDA has shifted from a distant gatekeeper to an active force shaping how health-tech companies build, sell, and exit. Regulatory cycles are…
- [AI’s Leap in Healthcare and Biotech: Insights from Our Latest Fireside Chat](https://www.averincapital.com/insights/ais-leap-in-healthcare-and-biotech-insights-from-our-latest-fireside-chat): Averin’s David Berry hosts a conversation with leaders from XYME, AWS, and Bioptic to explore how AI is transforming drug discovery, data infrastructure,…
- [Alzheimer’s Disease — Why We May Be Entering a New Era of Drug Development](https://www.averincapital.com/insights/alzheimers-disease-why-we-may-be-entering-a-new-era-of-drug-development): Advancements in trial design, disease hypothesis, therapeutic pathways and diagnostics give us hope that in the next 10-15 years, the life sciences…
- [How Startups Can Help Shift America to a Prevention First Health System](https://www.averincapital.com/insights/how-startups-can-help-with-the-transformation-to-preventation-care): The systemic disposition towards a treatment-first approach - focusing on managing illnesses - rather than a preventative-first approach is at the heart…
- [Continuous Glucose Monitors and the Future of Real-Time Biosensing](https://www.averincapital.com/insights/continuous-glucose-monitors-and-the-future-of-real-time-biosensing): CGMs are among the most important personal medical devices. While they are prevalent today, important changes in their design, accuracy, and the scope of…
- [Liquid Biopsies: Revolutionizing Non-Invasive Cancer Diagnostics](https://www.averincapital.com/insights/liquid-biopsies-revolutionizing-non-invasive-cancer-diagnosticsnbspnbsp): Groundbreaking improvements in the technologies for liquid biopsies have marked a tipping point in accuracy and reliability, resulting in a significant…
- [How Digital Diagnostics and Artificial Intelligence Can Transform Healthcare](https://www.averincapital.com/insights/digital-diagnostics-artificial-intelligence): AI has the potential to change the role of the doctor, and diagnostics is one of the first areas where we’re seeing a dramatic change. We discuss how…

## Links

- [LinkedIn](https://www.linkedin.com/in/davidberrymdphd)